In a significant development for the respiratory community, Sanofi has unveiled promising Phase 2 clinical trial data that could fundamentally reshape the management of alpha-1 antitrypsin deficiency (AATD)-related emphysema. The data, presented at the ATS 2026 conference, highlight the performance of efdoralprin alfa, an investigational recombinant human AAT-Fc fusion protein that demonstrates superior efficacy and a more patient-friendly dosing regimen compared to the current long-standing standard of care.
For nearly four decades, patients living with AATD have relied on weekly infusions of plasma-derived alpha-1 antitrypsin (pdAAT). While effective, this regimen is burdensome and often fails to keep protein levels within the protective physiological range consistently. The ElevAATe phase 2 study suggests that efdoralprin alfa may offer a robust, long-acting alternative, potentially signaling a new era for those affected by this rare genetic disorder.
RT’s Three Key Takeaways
- Superior Efficacy: Efdoralprin alfa, when administered every three weeks, achieved mean increases in functional AAT (fAAT) trough levels more than three times higher than the current weekly plasma-derived standard.
- Consistent Protection: Patients receiving the investigational therapy every three weeks maintained protective fAAT levels 100% of the time, compared to only 41% for those on the current standard of care.
- Improved Quality of Life: The extended half-life of the recombinant protein allows for significantly less frequent dosing, potentially reducing the treatment burden for patients and improving long-term adherence.
Understanding the Clinical Context: What is AATD?
Alpha-1 antitrypsin deficiency is a rare, inherited genetic condition that causes a deficiency of the AAT protein. Produced primarily in the liver, this protein is vital for protecting lung tissue from the destructive effects of inflammation and environmental pollutants. When AAT levels are low or absent, the delicate tissues of the lungs become susceptible to progressive deterioration, eventually leading to emphysema—a debilitating form of chronic obstructive pulmonary disease (COPD).
The clinical reality for AATD patients is often one of frustration. Despite the availability of augmentation therapy, many individuals remain in a state of "sub-protective" protein levels for significant portions of the month. This leaves them vulnerable to recurrent respiratory exacerbations and a faster decline in lung function. Because AATD is frequently under-diagnosed and mistaken for standard COPD, many patients remain underserved, highlighting the urgent need for therapeutic innovation.
Chronology of the ElevAATe Study
The journey of efdoralprin alfa through the clinical pipeline represents a targeted effort to modernize AATD care.
- Pre-Clinical Development: Researchers identified the need for a molecule with a longer half-life than traditional pdAAT. By engineering an AAT-Fc fusion protein, the team aimed to extend the duration of the drug in the bloodstream.
- Study Initiation: The global ElevAATe phase 2 trial (NCT05897424) was launched to evaluate the safety, tolerability, and pharmacokinetics of this new molecule.
- Trial Execution: The double-blind, randomized study enrolled 97 patients. Participants were divided into cohorts receiving either efdoralprin alfa every three weeks, every four weeks, or the current standard of care (weekly pdAAT).
- ATS 2026 Presentation: The primary analysis of the 32-week study was unveiled to the medical community, showing that the three-week dosing arm significantly outperformed the standard of care in achieving sustained protein levels.
- Current Status: Sanofi is now in active discussions with global regulatory bodies, including the FDA and the EMA, to define the pathway toward Phase 3 trials and eventual market approval.
Supporting Data: By the Numbers
The clinical metrics reported in the ElevAATe study provide compelling evidence for the potential superiority of efdoralprin alfa.
Pharmacokinetic Gains
At the 32-week mark, the primary endpoint focused on the mean change in average serum fAAT trough concentrations. The results were stark:
- Efdoralprin Alfa (every 3 weeks): 24.1 μM increase.
- Standard pdAAT (weekly): 7.6 μM increase.
This nearly threefold increase in troughs indicates that the recombinant therapy is significantly more effective at maintaining high concentrations of the protective protein in the blood.
Durability of Effect
Perhaps most impressive is the data regarding the consistency of coverage. In the three-week dosing group, fAAT levels remained above the recognized normal therapeutic threshold for 100% of the study period. In contrast, patients on the current weekly plasma-derived regimen remained above that threshold for only 41% of the study duration. This "trough" management is crucial, as the periods where levels drop below the threshold represent the "window of vulnerability" for lung tissue damage.
Safety and Tolerability
Safety is a primary concern for any new biologic. The trial reported that efdoralprin alfa was well tolerated, with a safety profile comparable to traditional pdAAT. Notably, no participants in the study discontinued the treatment due to adverse events. While common complications like COPD exacerbations, headaches, and COVID-19 were reported, the incidence of grade 2 or higher COPD exacerbations was numerically lower in the group receiving the three-week efdoralprin alfa regimen compared to the standard-of-care cohort, suggesting potential clinical benefit beyond just protein levels.
Official Responses and Expert Perspective
The medical community has reacted with cautious optimism, viewing these results as a long-awaited technological leap.
Igor Barjaktarevic, MD, PhD, associate professor at the David Geffen School of Medicine at UCLA and the study’s principal investigator, emphasized the transformative potential of the mechanism. "AATD presents a persistent clinical challenge," Barjaktarevic noted. "The ElevAATE data suggest efdoralprin alfa, through its mechanism of action, may be able to restore normal AAT levels and keep patients in that range for longer than the standard-of-care therapy, helping to address an unmet need of this disease with a restorative recombinant approach."
From the industry side, Sanofi’s commitment to the program underscores the strategic importance of the asset. Christopher Corsico, global head of development at Sanofi, stated, "The data demonstrate efdoralprin alfa, a restorative recombinant therapy designed to achieve a longer half-life than standard of care augmentation therapy, has the potential to raise and sustain fAAT levels within normal range with less frequent dosing. This could represent an important advancement in the treatment of AATD-related emphysema, offering patients new hope in a disease state where innovation has been limited over the past 40 years."
Implications for the Future of Respiratory Medicine
The success of this phase 2 trial has wide-reaching implications for both clinical practice and drug development in the rare disease space.
1. Shift in Patient Management
The move from weekly infusions to a three-week (or potentially four-week) dosing cycle would be a massive quality-of-life improvement. For patients, this means fewer hospital visits, less time attached to infusion pumps, and a greater sense of normalcy. Adherence to a monthly or tri-weekly schedule is statistically more likely to be maintained than a weekly regimen, potentially leading to better overall outcomes.
2. Validating Recombinant Technology
For decades, AATD therapy has relied on plasma donations, which are subject to supply chain volatility and the inherent limitations of human-derived proteins. Efdoralprin alfa’s success validates the use of recombinant fusion proteins in this space. By engineering the Fc region, the drug gains a longer half-life, bypassing the rapid clearance associated with traditional AAT. If successful, this could pave the way for a new generation of recombinant respiratory therapies.
3. Regulatory Pathway
The therapy has already secured "Fast Track" and "Orphan Drug" designations in the United States, as well as orphan designation in the European Union. These statuses are designed to accelerate the review process for treatments addressing serious or life-threatening conditions. Sanofi is currently running an open-label extension study to gather more long-term safety data, which will be vital for the eventual submission of a Biologics License Application (BLA).
4. Broadening the Horizon
While the current focus is on emphysema, the ability to maintain consistent AAT levels may have broader implications for other manifestations of AATD, including liver-related complications or skin issues associated with the deficiency. As clinicians and researchers look toward Phase 3, the industry will be watching to see if these pharmacokinetic successes translate into measurable slowing of lung function decline over the long term.
Conclusion
The ElevAATe study represents a rare moment of breakthrough in a field that has seen little change for 40 years. By providing a recombinant solution that stays in the body longer and maintains higher, more stable protein levels, Sanofi has positioned efdoralprin alfa as a potential new standard of care. As the clinical community awaits further results from the open-label extension and the subsequent Phase 3 trials, the primary takeaway is clear: the era of "sub-optimal" AAT protection may finally be drawing to a close. For patients, the promise of a more manageable and effective treatment is not just a scientific success—it is a beacon of hope for a better quality of life.
